BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15197503)

  • 1. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl)acetamide, [(18)F]EF3.
    Mahy P; De Bast M; Leveque PH; Gillart J; Labar D; Marchand J; Gregoire V
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1263-72. PubMed ID: 15197503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
    Mahy P; De Bast M; Gillart J; Labar D; Grégoire V
    Eur J Nucl Med Mol Imaging; 2006 May; 33(5):553-6. PubMed ID: 16523307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism.
    Mahy P; Geets X; Lonneux M; Levêque P; Christian N; De Bast M; Gillart J; Labar D; Lee J; Grégoire V
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1282-9. PubMed ID: 18317752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.
    Christian N; Bol A; De Bast M; Labar D; Lee J; Mahy P; Grégoire V
    Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1348-54. PubMed ID: 17334763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.
    Dubois L; Landuyt W; Cloetens L; Bol A; Bormans G; Haustermans K; Labar D; Nuyts J; Grégoire V; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):209-18. PubMed ID: 18690432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.
    Zanzonico P; O'Donoghue J; Chapman JD; Schneider R; Cai S; Larson S; Wen B; Chen Y; Finn R; Ruan S; Gerweck L; Humm J; Ling C
    Eur J Nucl Med Mol Imaging; 2004 Jan; 31(1):117-28. PubMed ID: 14523586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
    Busch TM; Hahn SM; Evans SM; Koch CJ
    Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is (18)F-FDG a surrogate tracer to measure tumor hypoxia? Comparison with the hypoxic tracer (14)C-EF3 in animal tumor models.
    Christian N; Deheneffe S; Bol A; De Bast M; Labar D; Lee JA; Grégoire V
    Radiother Oncol; 2010 Nov; 97(2):183-8. PubMed ID: 20304513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside.
    Piert M; Machulla HJ; Picchio M; Reischl G; Ziegler S; Kumar P; Wester HJ; Beck R; McEwan AJ; Wiebe LI; Schwaiger M
    J Nucl Med; 2005 Jan; 46(1):106-13. PubMed ID: 15632040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
    Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET imaging of tumor hypoxia using 18F-labeled pimonidazole.
    Busk M; Jakobsen S; Horsman MR; Mortensen LS; Iversen AB; Overgaard J; Nordsmark M; Ji X; Lee DY; Raleigh JR
    Acta Oncol; 2013 Oct; 52(7):1300-7. PubMed ID: 23962243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical evaluation of the fluorinated 2-nitroimidazole N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl) acetamide (SR-4554) as a probe for the measurement of tumor hypoxia.
    Aboagye EO; Maxwell RJ; Kelson AB; Tracy M; Lewis AD; Graham MA; Horsman MR; Griffiths JR; Workman P
    Cancer Res; 1997 Aug; 57(15):3314-8. PubMed ID: 9242466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
    Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
    J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.
    Souvatzoglou M; Grosu AL; Röper B; Krause BJ; Beck R; Reischl G; Picchio M; Machulla HJ; Wester HJ; Piert M
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1566-75. PubMed ID: 17447061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia.
    Josse O; Labar D; Georges B; Grégoire V; Marchand-Brynaert J
    Bioorg Med Chem; 2001 Mar; 9(3):665-75. PubMed ID: 11310602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.
    Rasey JS; Hofstrand PD; Chin LK; Tewson TJ
    J Nucl Med; 1999 Jun; 40(6):1072-9. PubMed ID: 10452326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio.
    Lehtiö K; Oikonen V; Nyman S; Grönroos T; Roivainen A; Eskola O; Minn H
    Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):101-8. PubMed ID: 12483416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.
    Ohshima Y; Hanaoka H; Tominaga H; Kanai Y; Kaira K; Yamaguchi A; Nagamori S; Oriuchi N; Tsushima Y; Endo K; Ishioka NS
    Ann Nucl Med; 2013 May; 27(4):314-24. PubMed ID: 23337966
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.